94 completed, 25 terminated, 9 recruiting, 6 unknown. 76 Phase 2, 43 Phase 1, 14 Not applicable, 14 Phase 3, 7 Phase 4.
Follow Chronic Myelogenous Leukemia: new trials by email Literature Review of Chronic Myelogenous Leukemia trials Research Report on Chronic Myelogenous Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP Asciminib single agent - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive | Phase 2 | Recruiting | Novartis Pharmaceuticals | 50 | 2026-04-28 | 2026-10-15 |
| ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis Cyclophosphamide, Fludarabine, Thiotepa - Acute Myelogenous Leukemia, Acute Lymphatic Leukemia | Phase 2 | Suspended | Leland Metheny | 20 | 2026-04-08 | 2026-09-10 |
| TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients TGRX-678, TKI - Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia - Chronic Phase | Phase 3 | Not yet recruiting | Shenzhen TargetRx Co., Ltd. | 180 | 2026-04-01 | 2026-03-24 |
| A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia TQB3911 tablets - Chronic Myelogenous Leukemia | Phase 1 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 120 | 2024-11-01 | 2024-11-04 |
| Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML) HS-10382+Flumatinib - Chronic Myelogenous Leukemia, CML Chronic Phase | Phase 1 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 100 | 2024-07-31 | 2024-07-31 |
| TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients TGRX-678 - Chronic Myelogenous Leukemia | Phase 1 | Recruiting | Shenzhen TargetRx Co., Ltd. | 90 | 2024-07-02 | 2026-10-20 |
| The Evaluation and Comparison of BCR-ABL p210 mRNA Transcripts (%IS Unit) Results Between Dr. PCR™ BCR-ABL1 Major IS Detection Kit (Optolane) and QXDx™ BCR-ABL %IS Kit (Bio-Rad) in Chronic Myeloid Leukemia Patients Chronic Myelogenous Leukemia | Unknown | Siriraj Hospital | 80 | 2024-03-20 | 2024-03-08 | |
| Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care. - Hematologic Malignancy, Leukemia | Recruiting | Children's Hospital Medical Center, Cincinnati | 30 | 2023-11-15 | 2026-10-01 | |
| Allo HSCT Using RIC and PTCy for Hematological Diseases Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 56 | 2023-05-01 | 2026-07-06 |
| CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies CliniMACS, Bone Marrow Transplant, Hyperfractionated Total Body Irradiation - Hematologic Diseases, Hematologic Malignancy | Phase 2 | Withdrawn | Baptist Health South Florida | 2022-09-01 | 2022-09-27 | |
| Asciminib Roll-over Study Asciminib single agent, Imatinib, Nilotinib - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 4 | Recruiting | Novartis Pharmaceuticals | 347 | 2022-08-30 | 2026-07-06 |
| Asciminib Treatment Optimization in ≥ 3rd Line CML-CP ABL001 40mg BID, ABL001 80mg QD, ABL001 200mg QD - Chronic Myelogenous Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 199 | 2021-10-13 | 2026-03-18 |
| HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Busulfan, Fludarabine, Total-body irradiation - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Phase 2 | Active not recruiting | Center for International Blood and Marrow Transplant Research | 300 | 2021-09-30 | 2026-03-18 |
| Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan - Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies | Phase 1 | Active not recruiting | Stanford University | 66 | 2021-09-07 | 2026-05-12 |
| TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients TGRX-678 - Chronic Myelogenous Leukemia | Phase 1 | Active not recruiting | Shenzhen TargetRx Co., Ltd. | 90 | 2021-03-29 | 2025-02-24 |
| Methods of T Cell Depletion Trial (MoTD) Thymoglobulin, Cyclophosphamide, Cyclosporine - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | University of Birmingham | 400 | 2021-02-22 | 2026-05-05 |
| Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy This is a non-interventional study - Acute Myelogenous Leukemia, Multiple Myeloma | Completed | Notable Labs | 119 | 2019-12-15 | 2022-04-05 | |
| Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies Fludarabine, Melphalan, Total Body Irradiation - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 34 | 2019-12-06 | 2025-12-11 |
| Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI) - Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Active not recruiting | Masonic Cancer Center, University of Minnesota | 22 | 2019-01-02 | 2026-01-06 |
| Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response. Asciminib add-on, Imatinib, Nilotinib - CML, Chronic Myelogenous Leukemia | Phase 2 | Completed | Novartis Pharmaceuticals | 104 | 2018-11-22 | 2026-04-21 |
Showing 20 of 151. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (151) · Leukemia, Myeloid, Acute (79) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (77) · Myelodysplastic Syndromes (65) · Hodgkin Disease (43) · Leukemia, Lymphocytic, Chronic, B-Cell (41) · Lymphoma, Non-Hodgkin (40) · Leukemia (35) · Multiple Myeloma (34) · Myeloproliferative Disorders (21) · Lymphoma (18) · Lymphoma, Mantle-Cell (17) · Primary Myelofibrosis (17) · Burkitt Lymphoma (15) · Lymphoma, Follicular (15)
Chronic Disease (151) · Disease Attributes (151) · Hemic and Lymphatic Diseases (151) · Pathologic Processes (151) · Pathological Conditions, Signs and Symptoms (151) · Bone Marrow Diseases (150) · Neoplasms by Histologic Type (150) · Leukemia, Myeloid (147) · Neoplasms (146) · Hematologic Diseases (145) · Myeloproliferative Disorders (130) · Leukemia (116) · Immune System Diseases (88) · Immunoproliferative Disorders (85) · Lymphatic Diseases (85)
Cyclophosphamide (29) · fludarabine (23) · Whole-Body Irradiation (20) · Mycophenolic Acid (19) · fludarabine phosphate (18) · Imatinib Mesylate (17) · nilotinib (16) · Tacrolimus (12) · Cyclosporine (11) · Busulfan (10) · Dasatinib (10) · Melphalan (9) · Granulocyte Colony-Stimulating Factor (8) · Clofarabine (6) · Cytarabine (6)
Novartis Pharmaceuticals (20) · M.D. Anderson Cancer Center (12) · Masonic Cancer Center, University of Minnesota (12) · National Heart, Lung, and Blood Institute (NHLBI) (5) · Baylor College of Medicine (4) · Bristol-Myers Squibb (4) · Astex Pharmaceuticals, Inc. (3) · Center for International Blood and Marrow Transplant Research (3) · Indiana University (3) · Shenzhen TargetRx Co., Ltd. (3) · University of California, San Francisco (3) · Virginia Commonwealth University (3) · Case Comprehensive Cancer Center (2) · Emory University (2) · H. Lee Moffitt Cancer Center and Research Institute (2)
United States (113) · Canada (19) · France (13) · Germany (12) · Spain (12) · Italy (10) · Japan (10) · United Kingdom (9) · Australia (8) · Poland (8) · South Korea (8) · Argentina (7) · Brazil (7) · China (7) · Netherlands (7)
Jorge E. Cortes, MD (3) · Claudio Brunstein, MD (2) · Jan Cerny, MD, PhD (2) · Leland Metheny, MD (2) · Minocher M Battiwalla, M.D. (2) · Robert Nelson, MD (2) · Thomas G. Martin, M.D. (2) · A Bacigalupo, Dr. (1) · A Bosi, Dr. (1) · A Ferrant, Dr (1) · A Gratwohl, Dr. (1)
PMID 35764773, PMID 16775235, PMID 17151364, PMID 17715389, PMID 18048643, PMID 18256322, PMID 18997171, PMID 19029442, PMID 19503090, PMID 19667400, PMID 19706886, PMID 19720924, PMID 20117965, PMID 20563869, PMID 21098399, PMID 22009536, PMID 22080968, PMID 22133778, PMID 22422826, PMID 23065508, PMID 23065514, PMID 23190221, PMID 23416850, PMID 23524640, PMID 23547655, PMID 23620574, PMID 23710698, PMID 23813900, PMID 24057647, PMID 24573552, PMID 24948656, PMID 25354103, PMID 25540064, PMID 25644958, PMID 25933833, PMID 25977584, PMID 26002753, PMID 26687426, PMID 26993758, PMID 27890073, PMID 27931243, PMID 28273028, PMID 28409328, PMID 29248669, PMID 29486663, PMID 29674506, PMID 29705733, PMID 29908231, PMID 29996726, PMID 30824040
P30CA015704 (2), U01HL069294 (2), 2004 (1), 2008 (1), 2009 (1), 2016 (1), 2018 (1), 2023 (1), 2025 (1), P01CA049639 (1), P30CA043703 (1), P50HL110787 (1), R01HL114591 (1), R21CA191594 (1), RC2CA148431 (1)